PMV Pharmaceuticals, Inc.
NMS: PMVPLive Quote
📈 ZcoreAI Score
Our AI model analyzes PMV Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PMVP Z-Score →About PMV Pharmaceuticals, Inc.
Healthcare
Biotechnology
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
📊 Fundamental Analysis
PMV Pharmaceuticals, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -55.4%, which indicates that capital utilization is currently under pressure.
At a current price of $1.32, PMVP currently sits at the 48th percentile of its 52-week range (Range: $0.81 - $1.88).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$70.39M
Trailing P/E
--
Forward P/E
-1.20
Beta (5Y)
1.40
52W High
$1.88
52W Low
$0.81
Avg Volume
622K
Day High
Day Low